India has approved the sale of generic versions of hepatitis C drugs. The move will bring down the standard course of sofosbuvir and ledipasvir (generic versions of Sovaldi and Harvoni) to $1,000 compared to $90,000 in U.S. and Europe.

Source: India approves sale of generic Hepatitis C drugs